Advertisement
Advertisement
Blood Cancer Talks
The Blood Cancer Talks podcast brings listeners an overview of the latest research and treatment strategies for hematologic malignancies. Hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD, meet with a wide range of experts in the field of hematologic oncology to discuss various topics in depth.
Raajit Rampal, MD, PhD, and the "Blood Cancer Talks" hosts discuss the diagnosis and management of essential thrombocythemia.
Dr Cliff describes an analysis of oncology drugs that were approved via the FDA Accelerated Approval Program over 10 years.
KarMMa-3 trial evaluated ide-cel in MM, while the CARTITUDE-4 trial evaluated cilta-cel in MM.
Dr. Tefferi discussed choosing the right mentors, balancing the clinical and the research, and becoming a "master physician."
Dr. Dispenzieri, of the Mayo Clinic, joins the "Blood Cancer Talks" hosts to discuss how to treat and manage AL amyloidosis.
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Dr. Eyre and the hosts discuss lymphoma abstracts from ASH 2023, including the FLAIR trial and the SYMPATICO trial.
Shernan Holtan, MD, and the hosts discuss recent data on graft versus host disease prophylaxis.
Dr. Derman and the hosts discuss myeloma abstracts from ASH 2023, including the PERSEUS trial and the KarMMa-3 trial.
Dr. Dickinson joins "Blood Cancer Talks" hosts to discuss phase I and II trials on DLBCL, follicular lymphoma, and more.
Alexander Perl, MD, joins the hosts to discuss the management of newly diagnosed and relapsed FLT3-positive AML.
The episode also discusses Dr. Raza's book, "The First Cell," which recounts stories of her patients with terminal cancer.
Kate Cwynarski, MBBS, PhD, of the University of College London, discusses the management of CNS lymphomas.
This episode of "Blood Cancer Talks" discusses the biology and management of multiple myeloma and the role of venetoclax.
The episode also highlights the S1211 study, which is the first randomized controlled trial with high-risk enrichment in MM.
Dr. Horwitz and the hosts focus on the three most common types of PTCL and the latest research.
Uma Borate, MBBS, joins the hosts to discuss CCUS and the latest data.
Dr. Brodsky and the hosts discuss treatment options for PNH and key recent research on the subject.
Dr. Bartlett and the hosts explore the history of first-line treatments for patients with Hodgkin lymphoma.
Dr. Jain discusses how he addresses the acute toxicities that can arise after CAR T-cell therapy.
The hosts discuss the latest data on CAR-T from the summer conference season.
Dr. Sekeres also speaks about his time on the FDA ODAC and his latest book, titled "Drugs and the FDA."
Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383.
Dr. Dreyling discusses the management of newly diagnosed MCL and considerations in light of the TRIANGLE trial.
The episode was inspired by an article titled “The Underrepresented Majority" by Andrés Gómez-De León, MD.
Dr. Tefferi discusses risk stratification systems for primary myelofibrosis, transplant considerations, and more.
Dr. Gertz and the hosts provide an overview of risk-stratification approaches and clinical trials in smoldering MM.
Dr. DeZern discusses the latest research in the management of acquired aplastic anemia.
Dr. Patel and the hosts discuss the phase III ASAP and Dauno-Double trials, menin inhibitors, and more.
This episode provides listeners with DLBCL management strategies and an overview of the latest research in the field.
Dr. Costa discusses the multiple uses of MRD in MM.
Dr. Stein discusses research on the impact of treatment delays, the RATIFY trial, and more.
